Download presentation
Presentation is loading. Please wait.
Published byBalázs Pásztor Modified over 5 years ago
1
High Expression of p300 Has an Unfavorable Impact on Survival in Resectable Esophageal Squamous Cell Carcinoma Yong Li, MD, Hao-Xian Yang, MD, Rong-Zhen Luo, MD, Ying Zhang, MD, Mei Li, MD, Xin Wang, MD, Wei-Hua Jia, PhD The Annals of Thoracic Surgery Volume 91, Issue 5, Pages (May 2011) DOI: /j.athoracsur Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions
2
Fig 1 p300 expression by immunohistochemical staining. (A, B) Normal esophageal mucosa demonstrated low expression of p300 protein in the nuclei of all esophageal squamous cells (magnification: A, ×40; B, ×400). (C, D). An esophageal squamous cell carcinoma (ESCC) case demonstrating a low expression level of p300 (magnification: C, ×40; D, ×400). (E, F) High expression level of p300 detected in esophageal squamous cell carcinoma (magnification: E, ×40; F, ×400). The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions
3
Fig 2 Receiver operating characteristic curve for p300 expression cutoff value was plotted by survival status. (AUC = area under the curve.) The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions
4
Fig 3 Disease-free survival (A, C, E) and overall survival (B, D, F) curves for esophageal squamous cell carcinoma patients according to their p300 expression status. (A, B) Disease-free survival and overall survival curves for patients with low and high expression levels of p300. (C, D) Disease-free survival and overall survival curves for patients with low and high expression levels of p300 at stage II. (E, F) Disease-free survival and overall survival curves for patients with low and high expression levels of p300 at stage III. The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.